Identification and validation of HOXC6 as a diagnostic biomarker for Ewing sarcoma: insights from machine learning algorithms and in vitro experiments
These findings highlight HOXC6 as a promising diagnostic biomarker for ES, demonstrating robust performance across multiple datasets. Additionally, its functional role suggests potential as a therapeutic target.
Authors
- Yonghua Pang (ORCID: https://orcid.org/0000-0002-7377-3202)
- Zhiyao Ren (ORCID: https://orcid.org/0000-0002-7598-9584)
- Yi Deng (ORCID: https://orcid.org/0000-0003-0659-2767)
- Xin Wang (ORCID: https://orcid.org/0000-0003-0217-7347)
- Jing Li (ORCID: https://orcid.org/0000-0002-9609-5846)
- Weinan Chen (ORCID: https://orcid.org/0009-0009-5233-6247)
- Yunyan Shen (ORCID: https://orcid.org/0009-0001-3051-4163)
- Jiahui Liang (ORCID: https://orcid.org/0009-0001-7548-7808)
Institutions
- Anhui Medical University (CN)
- Ghent University (BE)
- Linyi People's Hospital (CN)
- 117th Hospital of People's Liberation Army (CN)
- First Affiliated Hospital of Anhui Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-04-04
- DOI
- https://doi.org/10.3389/fimmu.2025.1449355
- Citations
- 1
- Primary Topic
- Cancer-related molecular mechanisms research
- Type
- article
- Field-Weighted Citation Impact
- 0.94